Novo Nordisk to open new AI hub in UK for drug discovery
The new hub will be located in the King’s Cross Knowledge Quarter, London
Read Moreby Jen Brogan | Jan 3, 2024 | News | 0
The new hub will be located in the King’s Cross Knowledge Quarter, London
Read Moreby John Pinching | May 26, 2023 | News | 0
Therapy has been developed for use among children and adolescents with growth hormone deficiency
Read Moreby John Pinching | Mar 8, 2023 | News | 0
NICE has recommended the use of semaglutide alongside a reduced-calorie diet and exercise
Read Moreby John Pinching | Sep 22, 2022 | News | 0
Data shows participants achieved greater treatment satisfaction when switching to icodec
Read Moreby John Pinching | Jul 11, 2022 | News | 0
Data shows a significant reduction in treated spontaneous and traumatic bleeds among haemophilia patients
Read Moreby John Pinching | Jun 28, 2022 | News | 0
New data will be released at the International Society on Thrombosis and Haemostasis Congress
Read Moreby Lucy Parsons | May 13, 2021 | News | 0
New results from a Phase IIIa study demonstrate benefits of drug for people with obesity ‘beyond weight loss’
Read Moreby Lucy Parsons | Apr 22, 2021 | News | 0
Study will include approximately 1,000 people with obesity or overweight with comorbidities
Read Moreby Lucy Parsons | Mar 24, 2021 | News | 0
Company had been aiming for approval in type 2 diabetes
Read Moreby Lucy Parsons | Feb 25, 2021 | News | 0
Production site in Måløv, Denmark manufactures products for oral diabetes treatment Rybelsus
Read Moreby Lucy Parsons | Feb 11, 2021 | News | 0
Participants lost on average 14.9% of their baseline body weight
Read Moreby Lucy Parsons | Feb 2, 2021 | News | 0
CHMP recommended marketing authorisation for human growth hormone therapy
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479